<?xml version="1.0" encoding="UTF-8"?>
<p>In response to the compelling public health need for a TB vaccine, in October 2017 the WHO convened experts and representatives of important stakeholder institutions involved in vaccine development to assist the WHO in a two-pronged effort to accelerate TB vaccine development. The first effort was dedicated to defining a preferred product characteristics (PPC) guidance document for new TB vaccines, now publicly available 
 <sup>
  <xref rid="ref-5" ref-type="bibr">5</xref>
 </sup>. The second was to convene a meeting providing an opportunity for the exchange of cutting-edge information relevant to TB vaccine development, from basic science to later stage research. The proceedings of this meeting are summarized in this document.
</p>
